GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sight Sciences Inc (NAS:SGHT) » Definitions » Piotroski F-Score

Sight Sciences (Sight Sciences) Piotroski F-Score : 5 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sight Sciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sight Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sight Sciences's Piotroski F-Score or its related term are showing as below:

SGHT' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 5
Current: 5

During the past 6 years, the highest Piotroski F-Score of Sight Sciences was 5. The lowest was 3. And the median was 4.


Sight Sciences Piotroski F-Score Historical Data

The historical data trend for Sight Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sight Sciences Piotroski F-Score Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 5.00 4.00 5.00

Sight Sciences Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 4.00 5.00 5.00

Competitive Comparison of Sight Sciences's Piotroski F-Score

For the Medical Devices subindustry, Sight Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -14.754 + -13.035 + -10.691 + -16.266 = $-54.75 Mil.
Cash Flow from Operations was -13.489 + -9.828 + -6.484 + -9.786 = $-39.59 Mil.
Revenue was 23.471 + 20.009 + 18.751 + 19.265 = $81.50 Mil.
Gross Profit was 20.09 + 17.332 + 15.975 + 16.472 = $69.87 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(196.641 + 185.289 + 176.641 + 166.651 + 155.56) / 5 = $176.1564 Mil.
Total Assets at the begining of this year (Mar23) was $196.64 Mil.
Long-Term Debt & Capital Lease Obligation was $34.50 Mil.
Total Current Assets was $152.09 Mil.
Total Current Liabilities was $11.69 Mil.
Net Income was -23.843 + -22.229 + -16.907 + -17.067 = $-80.05 Mil.

Revenue was 17.229 + 18.677 + 20.543 + 18.824 = $75.27 Mil.
Gross Profit was 14.493 + 15.749 + 16.878 + 15.776 = $62.90 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(258.59 + 240.749 + 225.234 + 213.073 + 196.641) / 5 = $226.8574 Mil.
Total Assets at the begining of last year (Mar22) was $258.59 Mil.
Long-Term Debt & Capital Lease Obligation was $33.81 Mil.
Total Current Assets was $193.65 Mil.
Total Current Liabilities was $15.15 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sight Sciences's current Net Income (TTM) was -54.75. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sight Sciences's current Cash Flow from Operations (TTM) was -39.59. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-54.746/196.641
=-0.27840583

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-80.046/258.59
=-0.30954793

Sight Sciences's return on assets of this year was -0.27840583. Sight Sciences's return on assets of last year was -0.30954793. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sight Sciences's current Net Income (TTM) was -54.75. Sight Sciences's current Cash Flow from Operations (TTM) was -39.59. ==> -39.59 > -54.75 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=34.499/176.1564
=0.19584301

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=33.81/226.8574
=0.14903635

Sight Sciences's gearing of this year was 0.19584301. Sight Sciences's gearing of last year was 0.14903635. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=152.089/11.693
=13.0068417

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=193.652/15.145
=12.78653021

Sight Sciences's current ratio of this year was 13.0068417. Sight Sciences's current ratio of last year was 12.78653021. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sight Sciences's number of shares in issue this year was 49.486. Sight Sciences's number of shares in issue last year was 48.405. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=69.869/81.496
=0.85733042

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=62.896/75.273
=0.83557185

Sight Sciences's gross margin of this year was 0.85733042. Sight Sciences's gross margin of last year was 0.83557185. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=81.496/196.641
=0.41444053

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=75.273/258.59
=0.29109014

Sight Sciences's asset turnover of this year was 0.41444053. Sight Sciences's asset turnover of last year was 0.29109014. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+1+0+1+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sight Sciences has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Sight Sciences  (NAS:SGHT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sight Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sight Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sight Sciences (Sight Sciences) Business Description

Traded in Other Exchanges
N/A
Address
4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Executives
Jeremy B. Hayden officer: Chief Legal Officer 2 MUSICK, 2 MUSICK, IRVINE CA 92618
Sam Boong Park officer: Chief Operating Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Paul Badawi director, 10 percent owner, officer: President and CEO C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
David Badawi director, officer: Chief Technology Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
D1 Capital Partners L.p. 10 percent owner 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Staffan Encrantz director C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Matthew Link officer: Chief Commercial Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Catherine Mazzacco director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Alison Bauerlein officer: See remarks 326 BOLLAY DRIVE, GOLETA CA 93117
James Rodberg officer: See Remarks C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Brenda Jane Larsen-becker director C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025
Jesse Selnick officer: Chief Financial Officer C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025
Daniel S. Sundheim 10 percent owner C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Erica J. Rogers director C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089

Sight Sciences (Sight Sciences) Headlines

From GuruFocus